In a highly unusual move, a U.S. Food and Drug Administration (FDA) advisory committee voted against FDA staff's own recommendation on July 23, 2026, recommending that two peptides — BPC-157 and KPV — be added to a list that could eventually let certain compounding pharmacies dispense them. Both peptides, along with five others under review, currently sit in a legal gray area for U.S. compounding.
This is an educational summary of what the Pharmacy Compounding Advisory Committee (PCAC) actually decided, why the vote is unusual, and — importantly — what it does not change about BPC-157's status today.
What the committee voted on
The PCAC convened on July 23 and 24 to debate whether to recommend that seven popular peptides be included on the 503A bulks list — the FDA-maintained list of bulk drug substances that traditional (503A) compounding pharmacies may legally use when preparing patient-specific medications. The seven substances under review were BPC-157, KPV, TB-500, MOTS-C, Emideltide, Epitalon, and Semax.
BPC-157 — a synthetic 15-amino-acid peptide that has been discussed in connection with ulcerative colitis — and KPV, discussed for inflammatory conditions, were the first two considered. Both received favorable recommendations.
- BPC-157: 8 members voted yes, 6 voted no, and 1 abstained.
- KPV: also recommended for inclusion.
Reporting from the meeting noted an audible gasp in the room after the BPC-157 tally was announced.
Why the vote is unusual
In the run-up to the meeting, FDA staff published preparatory documents concluding that the evaluation criteria "weigh against" placing both BPC-157 and KPV on the 503A bulks list. For BPC-157, staff cited limited effectiveness evidence and the existence of other FDA-approved treatments for ulcerative colitis; the only trial staff could locate was a meeting abstract describing a 46-person study in which the peptide was given as an enema, not an injection. For KPV, staff noted that none of the studies they identified were conducted in humans.
Advisory committees do not usually vote against the agency's own evidence review. Observers also noted that many of this committee's voting members consult with or are employed by companies that could promote or dispense peptides — a departure from the academics and researchers who typically populate these panels.
Why these peptides were being discussed at all
In 2023, the FDA flagged these substances as ones that "may present significant safety risks," effectively keeping compounding pharmacies from dispensing them. Supporters of the peptides argue that since the 2023 restriction, consumers have turned to unregulated alternative sources — including overseas suppliers — that carry their own risks. Opponents counter that little has changed on the scientific side since 2023, and that the underlying evidence remains thin.
What the opposition said
Several committee members and public commenters warned that the panel was reacting to market demand rather than clinical data. "I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science," said committee member Dr. Elizabeth Rebello of the University of Texas MD Anderson Cancer Center.
Public-health watchdogs raised a further concern: that placing a substance on the 503A bulks list could be misread by consumers as a signal of FDA endorsement, when the compounding pathway is a separate framework from FDA drug approval. Critics also argued that an easier compounding route could reduce the incentive for any company to run the rigorous trials that FDA approval requires.
What this vote is — and is not
This is the single most important section for readers trying to make sense of the headlines.
- This is not an FDA approval of BPC-157 or KPV.
- The committee's recommendation is not binding on the FDA.
- Any actual addition to the 503A bulks list must still go through a lengthy public rulemaking process — a proposed rule, a public comment period, and a final rule.
- The vote does not change the current U.S. status of BPC-157, which remains not FDA approved and not on the 503A bulks list today.
- BPC157.now does not sell, prescribe, dispense, or facilitate access to BPC-157, and this vote does not change that.
In other words, an advisory recommendation is a step in a process — not the end of one. We covered the range of possible outcomes ahead of the meeting in What the July 2026 FDA Advisory Meeting Could Mean for BPC-157, and the mechanics of the list itself in How the 503A Bulks List Works.
What happens next
The committee finished considering the remaining peptides on July 24. From here, the FDA will weigh the recommendations and decide whether to initiate rulemaking for any of the substances. Historically the agency follows PCAC recommendations in most cases, but it is not required to, and rulemaking can take considerable time. Until a final rule is published, nothing about the legal compounding status of these peptides changes.
We will continue to summarize official FDA materials — including any transcript, meeting minutes, or subsequent rulemaking notices — in plain language as they become available. You can follow each step on our regulatory tracker.
